Table 1.
Meta-Analysis Study Descriptions
| First Author, year | Gene, disease | Measure(s) | Outcome(s) | Timepoint(s) |
|---|---|---|---|---|
| (Aspinwall et al., 2008) | CDKN2A/p16, melanoma | Self-report questionnaire | Behavior Change | Baseline, immediately after, 1 month |
| (Aspinwall et al., 2009) | CDKN2A/p16, melanoma | Self-report questionnaire | Behavior Change, Behavioral Attitude | Baseline, immediately after, 1 month |
| (Aspinwall et al., 2013) | CDKN2A/p16, melanoma | Self-report questionnaire | Behavior Change | Baseline, 24 months |
| (Aspinwall et al., 2014) | CDKN2A/p16, melanoma | Self-report questionnaire | Behavior Change | Baseline, 24 months |
| (Chao et al., 2008)2 | ApoE-4, Alzheimer’s | Self-report questionnaire | Behavior Change | 12 months |
| (Christensen, Roberts, et al., 2016)1 | ApoE-4, Alzheimer’s and cardiovascular disease (CVD) | Self-report questionnaire | Behavior Change | 12 months |
| (Grant et al., 2013) | 21-allele risk score, type II diabetes | Self-report questionnaire | Behavior Change, Behavioral Attitude | Baseline, 12 weeks |
| (Green et al., 2009)1 | ApoE-4, Alzheimer’s | BAI, CES-D, IES | Anxiety, Depression, Disease-Specific | Baseline, 6 weeks, 12 months |
| (Heshka et al., 2008) | Factor V Leiden and prothrombin, thrombophilia | Self-report questionnaire | Behavior Change, Other Psychological | 12 months |
| (Hietaranta-Luoma et al., 2014)1 | ApoE-4, CVD | HTAS, self-report questionnaire | Behavior Change | Baseline, 10 weeks, 6 months, 12 months |
| (Hietaranta-Luoma et al., 2015)1 | ApoE-4, CVD | STAI. RBD, self-report questionnaire | Anxiety, Behavior Change, Other Psychological | 10 weeks, 12 months |
| (Kasparian et al., 2009) | CDKN2a, melanoma | HADS-A, HADS-D, IES, Self-report questionnaire | Anxiety, Behavior Change, Depression, Disease-Specific | Baseline, 2 weeks, 12 months |
| (Kullo et al., 2016) | 28-SNP risk score, coronary heart disease | STAI, PEFS, TAPAQ | Anxiety, Behavior Change | Baseline, 3 months, 6 months |
| (Legnani et al., 2006)1 | Factor V Leiden and G20210A, Thrombophilia | CBA-H, Self-report questionnaire | Other Psychological | Baseline, 20 days |
| (Sanderson et al., 2008)1 | GSTM1, lung cancer | IPQ-R, Self-report questionnaire | Anxiety, Behavior Change, Behavioral Attitude, Depression, Disease-Specific | Baseline, 1 week, 2 months |
| (Sanderson et al., 2009) | GSTM1, lung cancer | Self-report questionnaire | Behavior Change, Behavioral Attitude, Other Psychological | Baseline, immediately after, 6 months |
| (Vernarelli et al., 2010)2 | ApoE-4, Alzheimer’s | Self-report questionnaire | Behavior Change | 6 weeks |
Table 1. Descriptions of the final studies included in the meta-analysis. Descriptions include which gene(s) and/or mutation(s) and disease(s) were the results given in the study, the measures of different outcomes used, the outcomes measured and more specific descriptions, and the timepoints at which measures were taken. For descriptions of the outcomes, see Table S2. BAI= Beck Anxiety Inventory, CBA-H= Cognitive Behavioral Assessment Hospital Form, CES-D= Center for Epidemiologic Studies-Depression, HADS-A= Hospital Anxiety and Depression Scale-Anxiety, HADS-D= Hospital Anxiety and Depression Scale-Depression, HTAS= Health and Taste Screener, IES= Impact of Event Scale, IPQ-R= Revised Illness Perception Questionnaire, MICRA= Multidimensional Impact of Cancer Risk Assessment, PEFS= Percentage Energy from Fat Screener, RBD= Risk Behavior Diagnosis, STAI: State-Trait Anxiety Inventory, TAPAQ= Telephonic Assessment of Physical Activity Questionnaire.
outcomes reported in this study were adjusted, usually for demographics and baseline values.
outcomes reported in this study were adjusted, but non-adjusted values were reported and used.